Otros idiomas Asarina Pharma AB

Acciones

ASAP

SE0011641794

Mercado cerrado - Nasdaq Stockholm Otros sitios de cotización 12:47:54 30/04/2024			Varia. Cinco días.	Varia. 1 de enero.
0,968 ^SEK	-1,22 %		+7,56 %	+10,00 %

27/02	Asarina Pharma AB (publ) presenta los resultados del ejercicio cerrado el 31 de diciembre de 2023	CI
2023	Asarina Pharma AB (publ) informa de los resultados del semestre finalizado el 30 de junio de 2023	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

ASARINA PHARMA AB (PUBL) RELEASES YEAR-END REPORT 2023	27/02
Asarina Pharma AB Reports Earnings Results for the Full Year Ended December 31, 2023	27/02
Asarina Pharma AB changes Certified Adviser to Carnegie Investment Bank AB	30/11
Asarina Pharma updates on partnering and financials	16/11
Asarina Pharma AB (publ) releases First Half-Year Report (H1/2023)	23/08/23
Asarina Pharma AB Reports Earnings Results for the Half Year Ended June 30, 2023	23/08/23
ASARINA PHARMA - POSITIVE TOURETTE SYNDROME RESULTS TO BE PRESENTED AT ESSTS, 15TH EUROPEAN CONFERENCE ON TOURETTE SYNDROME AND TIC DISORDERS	24/05/23
Bulletin from the Annual General Meeting of Asarina Pharma AB (publ)	22/05/23
Asarina Pharma's positive Phase IIa Tourette Syndrome results to be presented at TicCon, the Virtual National Conference of the Tourette Association of America	08/05/23
Asarina Pharma's positive Phase IIa Tourette Syndrome results to be presented at TicCon, the Virtual National Conference of the Tourette Association of America	05/05/23
Asarina Pharma's Positive Phase IIa Tourette Syndrome Results to Be Presented At Ticcon, the Virtual National Conference of the Tourette Association of America	05/05/23
Asarina Pharma AB (publ) releases Annual Report 2022	01/05/23
Asarina Pharma AB (publ) releases Annual Report 2022	28/04/23
NOTICE OF ANNUAL GENERAL MEETING IN ASARINA PHARMA AB (PUBL)	18/04/23
Asarina Pharma publishes positive results from its Phase IIa study of Sepranolone in Tourette syndrome	03/04/23
Asarina Pharma publishes positive results from its Phase IIa study of Sepranolone in Tourette Syndrome	01/04/23
Asarina Pharma AB (publ) releases Year-End Report 2022	27/02/23
Asarina Pharma AB Reports Earnings Results for the Full Year Ended December 31, 2022	27/02/23
Last Patient Last Visit for landmark Tourette Syndrome study	02/02/23
Asarina Pharma - Patient recruitment completed in landmark Tourette syndrome study	17/10/22

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Asarina Pharma AB

Acciones

ASAP

SE0011641794

Otros idiomas

Filtros